Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 2/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8694783 | 0.87 | ALDH1A1 (0.46) | ALDH1A1LMNAHPGDRECQLPOLB | |
| SCHEMBL3227303 | 0.79 | LTA4H (0.47) | ALDH1A1RECQLDRD2DRD4DRD3 | |
| SCHEMBL1045802 | 0.78 | DRD2 (0.58) | HPGDPOLBDRD2DRD4DRD3 | |
| SCHEMBL3229694 | 0.78 | LTA4H (0.47) | ALDH1A1LMNAHPGDDRD2DRD3 | |
| SCHEMBL3229711 | 0.76 | ZDHHC2 (0.48) | ALDH1A1LMNADRD2DRD3HTT | |
| SCHEMBL3222529 | 0.76 | ZDHHC2 (0.48) | ALDH1A1LMNADRD2DRD3HTT | |
| SCHEMBL3213441 | 0.76 | ZDHHC2 (0.48) | ALDH1A1LMNADRD2DRD3HTT | |
| Acetic Acid SCHEMBL7350357 | 0.76 | HDAC3 (0.49) | ALDH1A1LMNARECQLPOLBKMT2A | |
| SCHEMBL10524805 | 0.76 | SMN1; SMN2 (0.47) | ALDH1A1LMNAPOLBKMT2AMEN1 | |
| SCHEMBL1033246 | 0.74 | HTR1B (0.42) | RECQLDRD2DRD4DRD3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1109542-A4 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-03-26 | — | — | EP | claimed |
| WO-2007087367-A9 | METHODS AND COMPOSITIONS FOR MODULATING THE MOBILIZATION OF STEM CELLS | SINAI SCHOOL MEDICINE (US) | 2007-09-13 | — | — | WO | claimed |
| US-20070190023-A1 | Methods and compositions for modulating the mobilization of stem cells | MOUNT SINAI SCHOOL OF MEDICINE | 2007-08-16 | — | — | US | claimed |
| WO-2007087367-A2 | METHODS AND COMPOSITIONS FOR MODULATING THE MOBILIZATION OF STEM CELLS | MOUNT SINAI SCHOOL OF MEDICINE (US) | 2007-08-02 | — | — | WO | claimed |
| US-20050187222-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds | NITROMED, INC. (US) | 2005-08-25 | — | — | US | claimed |
| US-20050065161-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses | NITROMED, INC. (US) | 2005-03-24 | — | — | US | claimed |
| US-6852736-B2 | Phenoxypropanolamines, preparation and therapeutic use thereof | SANOFI-SYNTHELABO (FR) | 2005-02-08 | — | — | US | claimed |
| EP-1242404-B1 | PHENOXYPROPANOLAMINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SYNTHELABO (FR) | 2004-07-07 | — | — | EP | claimed |
| US-20030105135-A1 | Phenoxypropanolamines, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2003-06-05 | — | — | US | claimed |
| US-20030040485-A1 | alpha/beta-adrenoceptors blockers and angiotensin converting enzyme inhibitors derived from hydroxyphenyl carboxylic acid and alcohol | CHEN ING-JUN (TW) | 2003-02-27 | — | — | US | claimed |
| EP-0064487-A1 | New substituted 3-(parasubstituted)phenoxy-1-alkylamino-propanol-2-s, as well as process for their preparation, pharmaceutical preparations containing same, and method for treating cardiac failure | Aktiebolaget Hässle (SE) | 1982-11-10 | — | — | EP | claimed |
| EP-0041491-A1 | New para-substituted 3-phenoxy-1-alkylamino-propanol-2-s having beta receptor blocking properties | Aktiebolaget Hässle (SE) | 1981-12-09 | — | — | EP | claimed |
| US-4263323-A | β-Receptor blocking compounds and treatment of cardiovascular disorders therewith | AKTIEBOLAGET HASSLE (SE) | 1981-04-21 | — | — | US | claimed |
| US-4263325-A | PHENOXY- AMINE DERIVATIVES | AKTIEBOLAGET HASSLE (SE) | 1981-04-21 | — | — | US | claimed |
| US-4258062-A | ISOPRENALINE ANTAGONISTS EFFECTING HEART RATE AND BLOOD PRESSURE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1981-03-24 | — | — | US | claimed |
| EP-0007294-A2 | Membrane stabilizing compounds having beta-receptor blocking activity, their preparation, method for treatment of arrhythmic conditions, and pharmaceutical preparations containing same | Aktiebolaget Hässle (SE) | 1980-01-23 | — | — | EP | claimed |
| US-4171370-A | Phenoxy-amino-propanols | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1979-10-16 | — | — | US | claimed |
| US-4161542-A | 3-(2-/P-HYDROXYPHENYL/-1-METHYLETHYLAMINO)-1-PHENOXY-2-PROPANOL/; | AKTIEBOLAGET HASSLE (SE) | 1979-07-17 | — | — | US | claimed |
| US-4145442-A | ADRENERGIC STIMULANTS; ANTAGONIST, ANTAGONISM | AKTIEBOLAGET HASSLE (SE) | 1979-03-20 | — | — | US | claimed |
| US-3996382-A | Phenoxy-hydroxypropylamines, their preparation, and method and pharmaceutical preparations for treating cardiovascular diseases | AKTIEBOLAGET HASSLE (SW) | 1976-12-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065161-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses | ADRB1, ADRB2, ADRB3 | ALDH1A1 584/4885LMNA 4057/4885HPGD 308/4885 |
| US-20050187222-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds | ADRB1, ADRB3, ADRA1D | ALDH1A1 628/4885LMNA 3062/4885HPGD 145/4885 |
| US-20030040485-A1 | alpha/beta-adrenoceptors blockers and angiotensin converting enzyme inhibitors derived from hydroxyphenyl carboxylic acid and alcohol | AGTR2, AGTR1, ADRB2 | ALDH1A1 141/4885LMNA 2535/4885HPGD 384/4885 |
| US-20030105135-A1 | Phenoxypropanolamines, preparation and therapeutic use thereof | CNR1, ADRB3, ADRB1 | ALDH1A1 637/4885LMNA 502/4885HPGD 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.